STEPHEN HAYWARD SINCLAIR
Medical Practice in Delaware
License number
Pennsylvania MD022777E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Delaware
Media, PA 19063
Media, PA 19063
Personal information
See more information about STEPHEN HAYWARD SINCLAIR at radaris.comName
Address
Phone
43 Apple Blossom Dr, Lancaster, PA 17602
637 Shadywood Dr, Perkasie, PA 18944
1208 Henry Ln, Gladwyne, PA 19035
216 N Broad St, Philadelphia, PA 19102
2024 Furniss Rd, Drumore, PA 17518
Professional information
See more information about STEPHEN HAYWARD SINCLAIR at trustoria.com
Dr. Stephen H Sinclair, Media PA - MD (Doctor of Medicine)
Dr. Stephen H Sinclair, Media PA - MD (Doctor of Medicine)
Specialties:
Ophthalmology
Address:
Sinclair Retina Associates
200 E State St SUITE 301, Media 19063
(610) 892-1708 (Phone)
200 E State St SUITE 301, Media 19063
(610) 892-1708 (Phone)
Certifications:
Ophthalmology, 1978
Awards:
Healthgrades Honor Roll
Languages:
English, Chinese
Hospitals:
Sinclair Retina Associates
200 E State St SUITE 301, Media 19063
Riddle Memorial Hospital
1068 West Baltimore Pike, Media 19063
200 E State St SUITE 301, Media 19063
Riddle Memorial Hospital
1068 West Baltimore Pike, Media 19063
Education:
Medical School
Harvard Medical School
Graduated: 1973
Massachusetts General Hospital
Massachusetts Eye and Ear Infirmary
Medical College Of Wisconsin
Harvard Medical School
Graduated: 1973
Massachusetts General Hospital
Massachusetts Eye and Ear Infirmary
Medical College Of Wisconsin
Vitreous Administration Of Erythropoietin
Vitreous Administration Of Erythropoietin
US Patent:
2009020, Aug 20, 2009
Filed:
Apr 28, 2007
Appl. No.:
12/299006
Inventors:
Guotong Xu - Shanghai, CN
Weiye Li - Shanghai, CN
Stephen H. Sinclair - Media PA, US
Weiye Li - Shanghai, CN
Stephen H. Sinclair - Media PA, US
Assignee:
SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CAS - Shanghai
International Classification:
A61K 38/22, C07K 14/505, A61P 27/02
US Classification:
514 8, 530397
Abstract:
A therapeutic composition for treating and/or preventing retinal disorder includes intravitreally or transsclerally administered erythropoietin.